We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




New Immunoassay Analyzer Introduced at 2016 AACC Annual Meeting

By LabMedica International staff writers
Posted on 12 Aug 2016
The recently renamed medical instrument manufacturer Siemens Healthineers (Erlangen, Germany) chose the July 31 - August 4, 2016, AACC Annual Meeting & Clinical Lab Expo (Philadelphia, PA, USA) as the venue for introducing its new Atellica Solution automated immunoassay and clinical chemical analyzer system.

In May 2016, Siemens Healthcare changed its name to Healthineers, a name that embodied the company’s pioneering spirit and engineering expertise in the healthcare industry. More...
It is unique and bold name and gives a new identity to the organization and to its employees who serve and inspire healthcare providers worldwide.

One of Healthineers' dynamic new products is the Atellica Solution. This highly flexible immunoassay and clinical chemistry solution features patented bi-directional magnetic sample-transport technology that allows the system to operate 10 faster than conventional conveyors. The platform boasts a multi-camera vision system and intelligent sample routing that allows independent control over every sample from routine assays to STATs.

Atellica Solution, which can handle more than 30 sample container types including pediatric and special containers, can be used as a stand- alone instrument, or it can be scaled up to 10 components with more than 300 customizable configurations. The system supports remote-access monitoring and control, which maximizes instrument uptime, with a broad and expanding assay menu using proven detection technologies.

"We engineered the Atellica Solution based on our customers' needs and extensive research of market trends," said Franz Walt, president of laboratory diagnostics at Siemens Healthineers. "The result is a game-changer that delivers control and simplicity, so our customers can focus on driving better business and clinical outcomes and spend less time managing operations."

The Atellica Solution is currently being evaluated by the Food and Drug Administration and is not yet available in the United States.

Related Links:
Siemens Healthineers
AACC Annual Meeting & Clinical Lab Expo

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Online QC Software
Acusera 24•7
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Pathology

view channel
Image: Overview of the uncertainty-aware lensfree computational pathology platform for automated HER2 assessment. A compact lensfree holographic imaging system captures diffraction patterns from immunohistochemically stained breast tissue samples, which are computationally reconstructed and analyzed using deep neural networks with Bayesian uncertainty quantification. (Photo courtesy of Ozcan Lab, UCLA)

Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer

Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.